Leflunomide Medac

Leflunomide, the active ingredient in Leflunomide Medac, is an immunomodulatory agent presented as a tablet for oral use. It treats rheumatoid arthritis and psoriatic arthritis in adult patients, helping to reduce inflammation and slow disease progression.

GNH USA supplies Leflunomide Medac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Leflunomide is a disease‑modifying antirheumatic drug that targets autoimmune joint disorders. - Rheumatoid arthritis: reduces joint inflammation, pain, and structural damage. - Psoriatic arthritis: improves skin lesions and joint symptoms. - Moderate to severe active disease refractory to other DMARDs: provides an alternative therapeutic option when first‑line agents are insufficient.

Leflunomide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Diarrhea: mild to moderate gastrointestinal upset. - Nausea: occasional feeling of queasiness. - Alopecia: reversible hair thinning. - Rash: skin irritation or erythema. - Elevated liver enzymes: mild hepatic transaminase rise. - Hypertension: increase in blood pressure readings.

Serious or Rare Side Effects: - Severe liver injury: potential hepatic failure requiring monitoring. - Stevens‑Johnson syndrome: rare, life‑threatening skin reaction. - Bone marrow suppression: pancytopenia or severe neutropenia. - Pulmonary toxicity: interstitial lung disease. - Severe infections: opportunistic infections due to immunosuppression. - Teratogenicity: fetal harm if exposure occurs during pregnancy.

Before initiating therapy, clinicians should assess patient suitability and monitor key parameters. - Pregnancy contraindication: avoid use in pregnant women and those planning conception. - Liver function monitoring: perform baseline and periodic liver enzyme tests. - Blood pressure monitoring: check regularly, especially in hypertensive patients. - Hematologic monitoring: periodic complete blood counts to detect cytopenias. - Renal impairment caution: adjust use in severe renal dysfunction. - Store at below 25°C: keep in the original pack, protect from moisture.

Leflunomide can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Methotrexate: combined hepatotoxicity risk. - Warfarin: increased anticoagulant effect. - Live vaccines: reduced vaccine efficacy and potential infection. - Carbamazepine and other enzyme‑inducing anticonvulsants: lower leflofuno­mid exposure. - TNF‑α inhibitors: heightened immunosuppression.

Moderate Interactions (Monitor Closely): - NSAIDs: additive liver toxicity. - Statins: increased risk of myopathy. - ACE inhibitors: possible aggravation of hypertension. - Oral contraceptives: reduced effectiveness, advise alternative contraception.